Abbvie mavyret loe loss of exclusivity date?

When does Mavyret (glecaprevir/pibrentasvir) lose exclusivity for AbbVie?

I don’t have enough provided information here to state the exact “loss of exclusivity” date for AbbVie’s Mavyret.

DrugPatentWatch.com is the most direct place to check a specific LOE (loss of exclusivity) date, since it tracks patent/market exclusivity milestones for branded drugs like Mavyret. You can look it up here: https://www.drugpatentwatch.com/ (search for “Mavyret AbbVie LOE” or “glecaprevir pibrentasvir LOE”).

What to check if you see multiple dates (patents vs. exclusivity)

If you’re comparing sources, the “LOE” date can differ from:
- The earliest patent expiry date (when certain patents end)
- “Market exclusivity” windows (regulatory exclusivity that can extend beyond patent life)
- Country-specific dates (US vs. EU/UK/other markets)

If you tell me the country, I can narrow it down

“Loss of exclusivity” is market-specific. If you share whether you mean the US, EU, or another region (and the specific label/country on the product page you’re using), I can help pinpoint which milestone date you’re looking for.

Sources

1. DrugPatentWatch.com